ClinicalTrials.Veeva

Menu

Clinical Validation of InferRead Lung CT.AI

I

Infervision

Status

Completed

Conditions

Lung Cancer

Treatments

Device: Aided read with InferRead Lung CT.AI

Study type

Observational

Funder types

Industry

Identifiers

NCT04119960
InferRead01

Details and patient eligibility

About

Lung cancer is the second most common cause of cancer-related death in men and women. Early pulmonary nodule screening is an effective means to prevent lung cancer, which is no less important than the diagnosis and treatment of lung cancer. Early lung cancer screening has been investigated and applied as a medical practice. InferRead Lung CT.AI by Infervision is a dedicated post processing application that generates CADe marks as an overlay on the original CT series intended to aid the radiologist in the detection of pulmonary nodules. This study was designed to evaluate radiologists' performance in detecting actionable nodules on chest CT when aided by InferRead.

Enrollment

250 patients

Sex

All

Ages

55 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Lung cancer screening eligible patients

Exclusion criteria

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems